2018 American Transplant Congress
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study
1TRANSFORM Study Group, Barcelona, Spain; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: TRANSFORM (NCT01950819) is the largest study conducted in de novo kidney transplant recipients (KTxRs) to evaluate the benefit of everolimus with reduced-dose calcineurin inhibitor…2018 American Transplant Congress
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA study was designed to compare efficacy, safety and outcomes on renal function [GFR] of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A…2018 American Transplant Congress
IgA Recurrence in a Single Center with a Protocol Biopsy Program
The objective of this study was to determine the rate of recurrence of IgA nephropathy in our program aided by protocol biopsies and protocol driven…2018 American Transplant Congress
Urine AngiotensinII Signature Proteins as Biomarkers of Fibrosis in Kidney Transplant Recipients
AngiotensinII (AngII), the main effector of the renin-angiotensin system (RAS), causes kidney interstitial fibrosis/tubular atrophy (IFTA). However, there are presently no markers of AngII renal…2018 American Transplant Congress
An Increase in Spot Urine Protein Excretion during the First Year after Kidney Transplantation Associates with Subclinical De-Novo Donor-Specific Antibodies and Microvascular Inflammation at 1-Year Surveillance Biopsies
Introduction. We investigated whether an increase in spot urine protein excretion during the first year after kidney transplantation associates with subclinical de-novo donor-specific antibodies (DSA)…2018 American Transplant Congress
Proteinuria is Associated with Increased Risk for Cardiovascular Disease after Kidney Transplantation
Introduction: Proteinuria is a risk factor for cardiovascular (CV) disease in the general population and occurs commonly after kidney transplantation. The association between proteinuria and…2018 American Transplant Congress
Evaluation of Salt Intake by 24-h Urinary Sodium Excretion in Kidney Transplant Patients
Background: Dietary recommendations for chronic kidney disease advise 3 to 6 g/day of dietary salt intake. We evaluated current adherence to dietary recommendations for CKD…2018 American Transplant Congress
High GFR in Kidney Donors is Associated with Increased Risk of Proteinuria and Diabetes
University of Minnesota, Minneapolis, MN.
Background: Measured glomerular filtration rate (GFR) has been part of the donor evaluation to rule out low GFR donors from taking undue risk for ESRD.…2018 American Transplant Congress
Urine Pellet Podocyte mRNAs Correlate Closely with Late Kidney Allograft Loss-of-Function
1Univ Michigan, Ann Arbor; 2Univ Kansas, Kansas City.
10-year surveillance biopsy studies (Nankivell,2003 & Stegall,2017) and podometric studies are compatible with progressive glomerulosclerosis (GS) contributing to long-term allograft loss-of-function.Thus one would expect to…2018 American Transplant Congress
Angiotensin II Type 1 Receptor Antibodies as Markers of Post Transplant Focal Segmental Glomerulosclerosis and Proteinuria
Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD.
Background:Angiotensin II type 1 receptor (AT1R) is highly expressed on the endothelial cells and podocytes, which play an essential role in the maintenance of vascular…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »